

**TREATMENT OF PURULENT-NECROTIC LESIONS OF THE LOWER
EXTREMITIES WITH MODERN DRUGS**

Ergashev Ulugbek Yusufjanovich

DSc., professor Head of department General surgery №2

Tashkent Medical Academy

Zokhirov Adkhamjon Rafiqovich

Assistant of department General surgery №2

Tashkent Medical Academy

Abdusalomov Behzod Alisher ogli

Assistant of department General surgery №2

Tashkent Medical Academy

Xo'jamurodova Gulzora Pirmamat qizi

3rd year student of the Faculty of Medicine and

Biology of the Tashkent Pediatric Medical Institute

Annotation

Study of the effect of the new drug "Rheomannisol" on vital organs, taking into account of diagnostics and prevention of pathophysiological aspects in the complex treatment of experimental diabetic foot syndrome.

Key words: experimental model of diabetic foot, experimental animals, diabetes mellitus, alloxan, surgical debridement, reomannisol.

Introduction

Currently, one of the leading places in terms of growth rates of morbidity, disability, and mortality was occupied by diabetes mellitus (DM) among the so-called "diseases of civilization" [1,4,5,17]. Today, over 460 million people are suffering globally from diabetes; according to the predicted facts announced by the International Diabetes Federation, by 2040 the number of patients will increase up to 642 million [11,12,18].

Diabetes mellitus is accompanied by the development of complications, including diabetic foot syndrome (DFS), one of the leading clinical symptoms of which is the persistence of an ulcer on the skin of the lower extremities [4,5].

<https://conferencea.org>

Delayed wound healing is one of the complications of the disease due to multiple factors including poor circulation [4,5,12,17], prolonged inflammation, and hyperglycemia. It is a common cause of morbidity and mortality in patients with DM [2,5,15,16]. When the wound becomes chronic, it is prone to developing foot ulcers, including neuropathy and foot deformities [6,13,17,18]. Foot ulcers in DM are the cause of more than 50% of all non-traumatic leg amputations [3,7,15]. Evidence has shown that hyperglycemia is one of the main factors contributing to slow wound healing by increasing cell apoptosis and decreasing cell survival in diabetic wounds. It has been shown to inhibit endothelial cell and fibroblast proliferation in humans [9], up to 75% slower in adult mice with DM compared to control mice [10].

At the present stage in experimental diabetology, the most widespread chemical model of diabetes mellitus uses substances that destroy β -cells of the islets of Langerhans [1,2, 11,12]. This study describes a model of diabetes mellitus in rats, induced by the introduction of a reduced dose of alloxan, which significantly reduces the number of animal deaths.

The alloxan model of diabetes mellitus is one of the most widespread and studied. It is actively used by researchers around the world. Alloxan is a structural analog of glucose, due to which it accumulates in pancreatic β -cells and leads to their death, followed by the development of diabetes. At the same time, damage to β -cells is accompanied by degenerative changes in the kidneys and liver, which leads to high mortality in laboratory animals on the first day after alloxan administration. The problem of violations of several types of metabolism with the introduction of alloxan, the prevalence of manifestations of oxidative stress as a typical pathological process in case of damage to the key organ involved in all types of metabolic processes (liver) dictate the need to prescribe pathogenetic drugs from the group of metabolic correctors with hepatoprotective and antioxidant orientation. One of the promising new drugs in this area is Rheomannisol (LLC "REKA-MED FARM" Republic of Uzbekistan) - a complex drug with antihypoxic, antioxidant, rheological, anti-shock, detoxifying, diuretic action. The main pharmacologically active substances are sodium succinate and mannitol.

Aim of the study. Study of the effect of the new drug "Rheomannisol" on endogenous intoxication and wound healing, taking morphological aspects into the complex treatment of experimental diabetic foot syndrome.

Materials and research methods. The work was done on experimental material. Healthy rats were selected for the experiment. Experimental studies were carried out on 140 outbred male rats weighing 220-250 g, kept in the Tashkent Medical Academy (TMA) vivarium. The rats were kept under optimal conditions, all rats lived in a room with a 12-hour light-dark cycle and

a constant temperature of 22-25°C, with free access to water. All rats were given a sufficient amount of a normal rodent diet ad libitum. (diet for rodents, State standard No. GOST R50258–92) and tap water daily. Operations and all manipulations with animals were carried out using general anesthesia, in compliance with the principles of humanity outlined in the directives of the European Community (86/609/EEC) and the Declaration of Helsinki, by the "Rules for working with experimental animals". The experimental animals were divided into 4 groups: the 1st group was intact; 2nd group –the creation of an experimental model of alloxan diabetes mellitus; 3rd control group - against the background of alloxan diabetes, the creation of an experimental model of a diabetic foot using traditional complex treatment; 4th experimental group - on an experimental model of diabetic foot - traditional treatment and reomannisol.

After a 24-hour fast, the rats were weighed. A 2% solution of alloxan diluted in 0.9% saline was administered intraperitoneally as a single dose, corresponding to a dose of 20, 15, 12 mg of alloxan per 100 g of animal weight. Food and water were given to animals only 30 minutes after drug administration. On the 3rd day, the level of glucose in the blood was assessed.

Results. The body bodyweight before the experiment varied from 220 to 250 g. Group 1 - intact animals (10 rats each), served as controls for groups 3 and 4. 2nd group –the creation of an experimental model of a diabetic foot, against the background of alloxan diabetes; To do this, 10 rats were injected intraperitoneally with 2% alloxan in an amount of 20 mg / 100 g. In this experimental group, in the 2nd experimental group, 8 rats died in the first 3 days as a result of hyperglycemic and hypoglycemic coma, which amounted to 80%. When examining the level of glucose in the blood with a glucometer of the remaining rats, it was 33.3 mmol/l and may have been higher, since the maximum range of the glucometer is 33.3 mmol/l. The remaining 2 rats sat in the corner, there were no reactions to external stimuli, they were sedentary when picked up. The animals did not touch the food. On the next day 4, the remaining rats died.

The second series of the second group of the experimental model of diabetes mellitus was created based on alloxan at a dose of 15 mg per 100 g from 10 rats. In this series of experiments, in the first 3 days the lethality was 50% (5 rats). The glucose levels of the survivors (5 rats) ranged from 29.8 to 33.3 mmol/l. During the next 4 days, the remaining rats died.

3rd series of the experiment of the 2nd group - administration of alloxan intraperitoneally at a dose of 12 mg per 100 g per 100 rats. During the next 72 hours, no lethal outcome was observed in rats, the range of blood glucose levels in rats varied between 15.5 - 17 mmol/L. In rats on the skin of the footpad pad of the right hind paw, a full-thickness rectangular wound measuring 2 mm × 5 mm was created with a scalpel. Rats were randomly divided into 2 groups, each group of 50 rats. So it was created 3 –a control group on 50 rats and 4 experimental groups n=50 rats. In both groups, until the end of the experiment (17 days), no death was recorded.

<https://conferencea.org>

A decrease in the activities of both enzymes (ALT, AST) followed the injections of rheomannisol in the experimental gr, out and on the 10th and 14th days, the numbers (ALT-37.5±0.62, AST-37.1±0.69; ALT-35.3± 0.54, AST-34.9 ± 1.04, respectively) indicate the normalization of the functional capacity of the liver, while in the control group, the activity of ALT and AST enzymes even on days 10, 14 (ALT-75.5 ± 1.1, AST-74.4±1.6; ALT-57.2±1.2, AST-53.4±1.3, respectively) 2 times higher than in the experimental one, and remain at a high level until the end of the experiment (Table 1).

Table 1. Biochemical parameters of animal blood in an experimental model of diabetic foot.

| Indexes Group of animals | Glucose, mmol/l | ALT, U/l | AST, U/l | Urea, mmol/l | Creatinine, mkmol/l | Total protein, g/l |
|-----------------------------|-----------------|---------------|---------------|--------------|---------------------|--------------------|
| | Day | | | | | |
| Intact | 5,8±0,19 | 34,0±1,0 | 33,4±1,1 | 5,1±0,20 | 61,5±2,0 | 74,1±1,2 |
| Control | 16,6±0,29*** | 75,1±1,8*** | 72,7±1,3*** | 13,8±0,27*** | 142,6±2,4*** | 58,4±1,0*** |
| Main | 15,2±0,43***^ | 70,4±1,0***^ | 66,7±1,1***^ | 13,5±0,27*** | 141,0±3,3*** | 58,8±0,63*** |
| 3 days | | | | | | |
| Control | 15,4±0,28*** | 82,8±1,4*** | 86,3±1,5*** | 15,0±0,40*** | 145,7±1,8*** | 55,5±0,73*** |
| Main | 12,0±0,31***^ | 52,6±1,6***^ | 48,4±1,4***^ | 9,8±0,29***^ | 97,6±2,1***^ | 60,1±0,86***^ |
| 7 days | | | | | | |
| Control | 14,1±0,20*** | 79,0±0,93*** | 79,0±1,5*** | 12,8±0,20*** | 127,6±1,8*** | 59,4±0,51*** |
| Main | 9,0±0,37***^ | 44,7±0,94***^ | 43,3±1,0***^ | 7,2±0,30***^ | 78,2±2,6***^ | 66,0±1,4***^ |
| 10 days | | | | | | |
| Control | 13,8±0,16*** | 75,5±1,1*** | 74,4±1,6*** | 12,2±0,24*** | 113,2±2,4*** | 63,3±0,71*** |
| Main | 7,3±0,21***^ | 37,5±0,62***^ | 37,1±0,69***^ | 5,8±0,19***^ | 68,7±1,2***^ | 73,5±0,80***^ |
| 14 days | | | | | | |
| Control | 12,9±0,19*** | 57,2±1,2*** | 53,4±1,3*** | 9,7±0,30*** | 96,7±1,6*** | 68,3±0,57*** |
| Main | 6,5±0,13***^ | 35,3±0,54***^ | 34,9±1,04***^ | 5,2±0,22***^ | 63,8±1,3***^ | 75,8±0,63***^ |

Note: *- significantly compared with the intact group (*-P<0,05; **-P<0,01; ***-P<0,001)
^ - significantly compared with the control group (^-P<0,05; ^^P<0,01; ^^P<0,001)

One of the laboratory signs of the development of renal dysfunction indicates the content of urea and creatinine in the blood plasma, in the first days of the experiments, in rats of the experimental and control groups were almost 2.5 times (without significant differences between these groups) higher than in the intact group (tables No. 1). After 3-fold intraperitoneal administration of the drug reomannisol, on the 3rd day, the experimental group showed a noticeable decrease in the values of urea (9.81 ± 0.29) and creatinine (97.6 ± 2.1) by 1.5 times relative to the values control group (urea- 15.0 ± 0.40 ; creatinine- 145.7 ± 1.8). On the 7th day in the groups of rats treated with reomannisol, the levels of urea and serum creatinine (7.2 ± 0.30 and 78.2 ± 2.6 , respectively) were lower compared to control animals (12.8 ± 0.20 and 127.6 ± 1.8 , respectively) by almost 1.7 times. On days 10, 14, urea values and creatinine clearance (urin- 5.8 ± 0.19 ; creat- 68.7 ± 1.2 ; urine- 5.2 ± 0.22 ; creat- 63.8 ± 1.3 respectively) in the experimental group were close to those of the intact group of rats (urea- 5.1 ± 0.20 ; creatinine- 61.5 ± 2.0). However, in the control group, it was accompanied by a higher value of urea and creatinine clearance, and on the 14th day, they were urea- 9.7 ± 0.30 and creatinine- 96.7 ± 1.6 - an average of 1.7 times higher than the values of the experimental group (Table 1).

Conclusions

The results of biochemical studies demonstrate positive dynamics in experimental animals with a diabetic foot model when using the drug reomannisol. This was manifested by the fact that by the 10th day there was a decrease and normalization of the level of glucose in the peripheral blood, indicators of renal clearance (urea, creatinine), liver (ALT, AST, albumins).

References

1. Andreeva L.I., Kozhemyakin L.A. Modification of the method for determining lipid peroxides in the test with thiobarbituric acid. Laboratory business, 1988, 11: P.41-46.
2. Bensman, V.M. Surgery for purulent-necrotic complications diabetic foot / V.M. Bensman. - M.: Medpraktika-M, 2015. - P.495.
3. Bensman, V.M. Surgery of purulent-necrotic lesions of the lower extremities / V.M. Bensman. - Krasnodar: Media - retard, 2015.
4. Kalf Kalif Ya.Ya. About LII and its practical significance / Y. Y. Kalf-Kalif // Medical business. - 1941. - No. 1. - S. 31-33.

5. Kovaleva, M. A. Animal modeling of the “diabetic foot” against the background of experimental streptozotocin-induced diabetes / M. A. Kovaleva, M. N. Makarova, M. A. Goryacheva, Ya. A. Gushchin, V. G. Makarov, EA Khomutnikov // International Journal of Experimental Education. - 2016. - No. 7. - P.47–51.
6. Ostrovsky, V. K. Evaluation of the severity of the course and determining the prognosis in patients with acute pancreatitis / V. K. Ostrovsky, P. N. Rodionov, S. V. Makarov // Khirurgiya. Journal them. N.I. Pirogov: scientific and practical journal. - 2011. - No. 8. - P.47–50.
7. Tarasenko A. V., Alekseev S. A., Fedorov V. N., Dudko A. A. Evaluation of indicators of endogenous intoxication and prediction of adverse outcomes in patients with various forms of necrotizing pancreatitis // Original scientific publications. - 2016. P.59-62.
8. Арипова Д. Ш. и др. Энтеросорбционные препараты—новый этап в комплексном лечении хронической почечной недостаточности и уремического синдрома //2017 год. – С. 76.
9. Khabirov T.Sh. The level of reactive response of neutrophils as an indicator of the severity of endogenous intoxication in abdominal sepsis // Proceedings of the IX Congress of SFULT. - Lugansk, 2002. - p. 223.
10. Ergashev U. Y. et al. Treatment of idiopathic thrombocytopenic purpura: prevention of hormonal complications in the stomach and duodenum //Central Asian Journal of Medicine. – 2020. – Т. 2020. – №. 2. – С. 5-28.
11. Ergashev U.Y., Mustafakulov G.I., Muminov A.T., Minavarkhujaev R.R., Yakubov D.R., Ernazarov Kh.I., Zohirov A.R. 2021. The role of minimally invasive technologies in the treatment of liver cavities. *Frontiers in Bioscience-Landmark*, 8, 82-89, DOI:10.52594/4945
12. Ergashev U. Y., Ernazarov Kh. I., Zohirov A. R., Alzabni I. D. 2022. Complex Treatment of Experimental Model of Diabetic Foot Syndrome. *American Journal of Medicine and Medical Sciences* 2022, 12(5): 471-480. DOI:
13. International Diabetes Federation. *IDF Diabetes Atlas, 10th edn.* Brussels, Belgium: International Diabetes Federation, 2021. www.diabetesatlas.org.
14. Kato, J., Kamiya, H., Himeno, T., Shibata, T., Kondo, M., Okawa, T., Fujiya, A., Fukami, A., Uenishi, E., Seino, Y., Tsunekawa, S., Hamada, Y., Naruse, K., Oiso, Y., and Nakamura, J. 2014. mesenchymal stem cells ameliorate impaired wound healing through enhancing keratinocyte functions in diabetic foot ulcerations on the plantar skin of rats. *J. Diabetes Complications* 28: 588–595. [medline] [CrossRef].

15. Karimov, X. Y., Ergashev, U. Y., & Yakubov, D. R. (2022). Complex treatment in severe forms of acute paraproctitis. *Web of Scientist: International Scientific Research Journal*, 3(9), 199-203.
16. Laliou R.C., Brouwer R.J., Ubbink D.T., Hoencamp R., Bol Raap R., van Hulst R.A. Hyperbaric oxygen therapy for nonischemic diabetic ulcers: A systematic review. *Wound Repair Regen.* 2020;28(2):266–275. DOI: 10.1111/wrr. 12776.
17. Lau, T.w., Sahota, D.S., Lau, C.H., Chan, C.m., Lam, F.C., Ho, Y.Y., Fung, K.P., Lau, C.B., and Leung, P.C. 2008. an in vivo investigation on the wound-healing effect of two medicinal herbs using an animal model with foot ulcer. *Eur. Surg. Res.* 41: 15–23. [medline] [CrossRef]
18. Pangui H.L., Amal M., Haraj N.E., Aziz S.E., Chadli A. Growth factors in trophic disorders in diabetics. *Endocr abstr.* 2021; DOI: 10.1530/endoabs.73. aep347.
19. Tchanque-Fossuo C.N., Dahle S.E., Lev-Tov H., West K.I.M., Li C.S., Rocke D.M., Isseroff R.R. Cellular versus acellular matrix devices in the treatment of diabetic foot ulcers: Interim results of a comparative efficacy randomized controlled trial. *J Tissue Eng Regen. Med.* 2019;13(8):1430–1437. DOI: 10.1002/ term.2884.
20. The search for the ideal thin skin flap: superficial circumflex iliac artery perforator flap--a review of 210 cases / T.L. Goh, S.W. Park, J.Y. Cho [et al.] // *Plast. Reconstr. Surg.* – 2015. – Vol. 135, № 2. – P. 592-601.
21. Ирискулов Б. У., Эргашев У. Ю., Минавархужаев Р. Р. Эффективность озонотерапии у больных с ампутациями нижних конечностей. – 2021.